publication date: Oct. 12, 2018

Trials & Tribulations

Biomarker linked to increased survival rates among certain brain tumor patients


By Arnab Chakravarti

Chair of Radiation Oncology,

The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Study shows DNA biomarker can be used to predict outcomes for high risk low grade gliomas

Brain tumors can be tricky to treat because there is such a wide range of outcomes. Some patients succumb to the disease within months, others live years beyond their diagnosis.

Medical experts have long needed better methods of determining which patients are likely to have more aggressive tumors. Genetic testing is fast becoming a gateway of hope.

The National Brain Tumor Society reports an estimated 700,000 people in the United States are living with the diagnosis of a primary brain tumor. Annually it is estimated 16,616 people will die from a malignant brain tumor.

Our new study is the first published data showing that a DNA-level biomarker can be used to predict survival outcomes in patients with high-risk, low-grade gliomas. This data represents the first clinical trial-based evidence of the prognostic importance of MGMT promoter methylation in patients with grade II gliomas.

Specifically, patients with MGMT methylated tumors were found to be more than twice as likely to survive after combination temozolomide and radiation treatment when compared … Continue reading Biomarker linked to increased survival rates among certain brain tumor patients

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.